Insight Molecular Diagnostics Inc.
Close on Oct 19, 2026
- Market cap
- $106.21M
- P/E (TTM)
- –
- Dividend yield
- –
About Insight Molecular Diagnostics
In Vitro & In Vivo Diagnostic Substances, SIC 2835
The company is a diagnostics technology developer focused on decentralized molecular testing kits, primarily for monitoring transplanted organ rejection. Its diagnostic portfolio features the GraftAssure family of assays, which quantify donor-derived cell-free DNA to assess graft organ health. These include a laboratory-developed test, a research-use-only test kit, and an in-vitro diagnostic kit under development. Additionally, the company maintains research-stage oncology programs and provides assay development and clinical testing services through its laboratory operations. Initial target customers comprise hospitals, transplant centers, research facilities, and local laboratories.
Operations span facilities in the United States and Germany, including research and development laboratories in Nashville, Tennessee, and Göttingen, Germany. The company also operates a certified and accredited clinical services laboratory in Franklin, Tennessee. Its principal executive and administrative offices are located in Nashville, Tennessee.
Summary of the business section of Insight Molecular Diagnostics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Insight Molecular Diagnostics Inc.
- Founded
- 2009
- Headquarters
- Nashville, TN
- Address
- 2 International Plaza Dr., Suite 510 37217
- Phone
- (949) 409-7600
- Website
- imdxinc.com
- Employees
- 58, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- California
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., Costa Mesa, CA
Stock & identifiers
- Ticker
- IMDX
- Exchange
- Nasdaq
- Shares outstanding
- 33M, Aug 3, 2026
- Public float
- $32.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Aug 10, 2023; 1-for-20 reverse, Jul 25, 2023
- SEC CIK
- 1642380
- CUSIP
- 68235C206
- ISIN
- US68235C2061
- LEI
- 549300BIYAW8GO410287
- EIN
- 27-1041563
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Josh Riggs | CEO and President, Director | 38,365 |
| James Yang Liu | VP ACCT, Cntlr, Treasurer, PAO | 6,289 |
| Andrea S. James | Chief Financial Officer | 206,060 |
| Andrew Arno | Director | 164,589 |
| Andrew J. Last | Director | 58,752 |
| Lou Silverman | Director | 55,807 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 CEO | $2.59M | $4.43M | $1.07M | $17 | – |
| FY2025 Non Peo Neo | $1.07M | $1.79M | $1.07M | $17 | – |
| FY2024 CEO | $786.08K | $489.35K | $678.54K | $5 | – |
| FY2024 Non Peo Neo | $678.54K | $563.82K | $678.54K | $5 | – |
| FY2023 CEO | $4.61M | $2.47M | $2.42M | $5 | – |
| FY2023 Non Peo Neo | $2.42M | $378.11K | $2.42M | $5 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 58 persons, of which 55 were on a full-time basis and 3 were on a part-time basis.”
Corporate history
Events identified from SEC filings